BR9915811A - Vacina a base de peptìdeo para influenza - Google Patents

Vacina a base de peptìdeo para influenza

Info

Publication number
BR9915811A
BR9915811A BR9915811-6A BR9915811A BR9915811A BR 9915811 A BR9915811 A BR 9915811A BR 9915811 A BR9915811 A BR 9915811A BR 9915811 A BR9915811 A BR 9915811A
Authority
BR
Brazil
Prior art keywords
epitopes
influenza
epitope
influenza virus
hla molecules
Prior art date
Application number
BR9915811-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Ruth Arnon
Tamar Ben-Yedidia
Raphael Levi
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of BR9915811A publication Critical patent/BR9915811A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR9915811-6A 1998-11-30 1999-11-28 Vacina a base de peptìdeo para influenza BR9915811A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12733198A IL127331A0 (en) 1998-11-30 1998-11-30 Peptide-based vaccine for influenza
PCT/IL1999/000640 WO2000032228A2 (en) 1998-11-30 1999-11-28 Peptide-based vaccine for influenza

Publications (1)

Publication Number Publication Date
BR9915811A true BR9915811A (pt) 2001-08-21

Family

ID=11072200

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915811-6A BR9915811A (pt) 1998-11-30 1999-11-28 Vacina a base de peptìdeo para influenza

Country Status (15)

Country Link
US (3) US6740325B1 (cg-RX-API-DMAC7.html)
EP (2) EP1135159A2 (cg-RX-API-DMAC7.html)
JP (1) JP2002531415A (cg-RX-API-DMAC7.html)
KR (1) KR100703571B1 (cg-RX-API-DMAC7.html)
AT (1) ATE556719T1 (cg-RX-API-DMAC7.html)
AU (1) AU766883B2 (cg-RX-API-DMAC7.html)
BR (1) BR9915811A (cg-RX-API-DMAC7.html)
CA (1) CA2352454C (cg-RX-API-DMAC7.html)
DK (1) DK2204187T3 (cg-RX-API-DMAC7.html)
ES (1) ES2389611T3 (cg-RX-API-DMAC7.html)
HK (1) HK1040620A1 (cg-RX-API-DMAC7.html)
IL (3) IL127331A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ511918A (cg-RX-API-DMAC7.html)
PT (1) PT2204187E (cg-RX-API-DMAC7.html)
WO (1) WO2000032228A2 (cg-RX-API-DMAC7.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
WO2002026252A1 (en) * 2000-08-10 2002-04-04 Tsinghua University A vaccine for influenza virus and its preparation
FI20031536A0 (fi) * 2003-10-20 2003-10-20 Biotie Therapies Oyj Korkean affiniteetin ligandit influenssavirukselle ja menetelmät niiden valmistamiseen
PL1692265T3 (pl) 2003-11-04 2011-12-30 The Administrators Of The Tulane Educational Fund Sposób zapobiegania fuzji wirus:komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
WO2006074303A2 (en) * 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
AR052195A1 (es) 2005-01-19 2007-03-07 Vaxinnate Corp Composiciones de patrones moleculares asociados a patogenos en metodos de uso
FI20060200A0 (fi) * 2005-04-20 2006-02-27 Glykos Finland Oy Menetelmä ihmisen influenssaviruksen sialihahappositoumisspesifisyyden analysoimiseksi
KR20080027777A (ko) * 2005-06-01 2008-03-28 배리에이션 바이오테크놀로지스 아이엔씨. 펩티드­기초 인플루엔자 백신 제제
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US7468187B2 (en) * 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
US20090169576A1 (en) * 2005-10-26 2009-07-02 Roberto Crea Influenza combinatorial antigen vaccine
AU2006311752A1 (en) * 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center CD40 ligand fusion protein vaccine
DK1968632T3 (da) 2005-12-06 2012-07-16 Yeda Res & Dev Forbedret influenzavaccine
PL2478916T3 (pl) * 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
ES2555544T3 (es) * 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
US20080208486A1 (en) * 2006-03-23 2008-08-28 Jari Natunen Integrated System, Device and Use Thereof
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
US20110129438A1 (en) * 2006-06-28 2011-06-02 James Robert Swartz Immunogenic protein constructs
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
WO2008112218A2 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
WO2009016639A2 (en) 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
CA2721800A1 (en) 2008-04-21 2009-10-29 Nanobio Corporation Nanoemulsion influenza vaccine
JP2011519834A (ja) * 2008-04-25 2011-07-14 インスティチュート フォー システムズ バイオロジー フラジェリンポリペプチドワクチン
WO2009135152A2 (en) 2008-05-02 2009-11-05 University Of Rochester Arrayed detector system for measurement of influenza immune response
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
MX2012000372A (es) 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
CA2840982C (en) 2011-07-06 2022-06-07 Vira BITKO Human respiratory syncytial virus vaccine
JP6205360B2 (ja) 2011-08-22 2017-09-27 ナノバイオ コーポレーション 単純ヘルペスウイルスのナノエマルジョンワクチン
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP4008354A1 (en) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
CA2840997A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
CN103961701B (zh) 2013-02-05 2018-09-14 日东电工株式会社 疫苗组合物
CA2840954A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
CA2840937A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
CN103961700A (zh) 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
CA2841014A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Tape preparation of wt1 peptide cancer vaccine for transdermal administration
CA2840941A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for transdermal administration
CN103961702B (zh) 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
CN103961697A (zh) 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
RU2531235C2 (ru) * 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
CN103901202B (zh) * 2014-04-04 2015-08-12 中国人民解放军成都军区疾病预防控制中心 基于共有表位甲型流感病毒抗体通用型竞争性elisa检测方法
CN106687138B (zh) 2014-09-03 2021-10-15 日东电工株式会社 包含双膦酸盐剂的细胞性免疫用疫苗药物组合物
EP3189852B1 (en) 2014-09-03 2021-04-07 Nitto Denko Corporation Bisphosphonate-containing pharmaceutical vaccine composition for humoral immunity
WO2017022793A1 (ja) 2015-08-06 2017-02-09 日東電工株式会社 免疫誘導促進組成物及びワクチン医薬組成物
BR112019013402A2 (pt) * 2016-12-28 2020-03-03 Invvax, Inc. Vacinas de influenza
WO2026101847A1 (en) 2024-11-05 2026-05-15 Bluewillow Biologics, Inc. Methods of influenza vaccination and compositions for the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
WO1997044667A2 (fr) * 1996-05-21 1997-11-27 Institut Pasteur Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza

Also Published As

Publication number Publication date
IL143367A (en) 2006-09-05
HK1040620A1 (zh) 2002-06-21
HK1145448A1 (en) 2011-04-21
KR20010089512A (ko) 2001-10-06
ATE556719T1 (de) 2012-05-15
NZ511918A (en) 2003-08-29
AU1406600A (en) 2000-06-19
PT2204187E (pt) 2012-08-10
US7514086B2 (en) 2009-04-07
AU766883B2 (en) 2003-10-23
CA2352454A1 (en) 2000-06-08
EP2204187B1 (en) 2012-05-09
WO2000032228A3 (en) 2000-10-05
EP2204187A1 (en) 2010-07-07
JP2002531415A (ja) 2002-09-24
US20050002954A1 (en) 2005-01-06
US20070122424A1 (en) 2007-05-31
IL143367A0 (en) 2002-04-21
US6740325B1 (en) 2004-05-25
CA2352454C (en) 2013-02-05
IL127331A0 (en) 1999-09-22
US7192595B2 (en) 2007-03-20
EP1135159A2 (en) 2001-09-26
KR100703571B1 (ko) 2007-04-05
ES2389611T3 (es) 2012-10-29
DK2204187T3 (da) 2012-08-20
WO2000032228A2 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
IL127331A0 (en) Peptide-based vaccine for influenza
JP2002531415A5 (cg-RX-API-DMAC7.html)
UY27552A1 (es) 17a- alquil- 17b- oxi-estratrienos y productos intermediarios para su preparacinn, uso de los 17a-alquil-17b-oxi-estratrienos para obtener medicamentos y preparados farmacéuticos.
DE69808130D1 (de) Adamantan-derivate
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
ES2619332T3 (es) Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
Schild et al. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide.
ES2121830T3 (es) Procedimiento para la preparacion a escala industrial de un concentrado de factor de willebrand humano normalizado de pureza muy elevada apropiado para uso terapeutico.
AR062931A2 (es) Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos
PT1036058E (pt) Deribvados de adamantano
ES2060603T3 (es) El uso de la proteina vp6 nucleocapsida de rotavirus en composiciones de vacunas.
AR038568A1 (es) Anticuerpos anti-a beta y su uso
DK0528859T3 (da) Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer
NO20023829D0 (no) Proteosom influensavaksine
EA200900784A1 (ru) Вакцины, включающие антиген из четырех штаммов вируса гриппа
BR0111667A (pt) Novos compostos
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
BR9811475A (pt) Conjugados imunogênicos compreendendo uma porina meningocóccica de grupo b e um polissacarìdeo de h. influenzae
UY26297A1 (es) Vacuna
BRPI0519705A2 (pt) composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
IL106968A0 (en) Potentiation of immunogenic response
FI964045A0 (fi) CCK:ta tai gastriinia säätelevä 5-heterosykli-1,5-bentsodiatsepiinejä
AR056137A1 (es) Un conjugado peptido inmunoglobulina y su uso como antiviral
SE8604991L (sv) Tillvexthemmande peptid fran ormgift
Beauverger et al. Serotype-specific and canine distemper virus cross-reactive H-2Kk-restricted cytotoxic T lymphocyte epitopes in the measles virus nucleoprotein

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1933 DE 22/01/2008.